As a young boy, Clay Siegall was always interested in medicine, technology and overcoming diseases. He believed that there are unlimited ways through which man could intervene in the course of nature and improve the health and wellness of sick individuals. As a zoology student at the University of Maryland, he continued to keep an eye on the developments in the medicine world. According to his recent interview with the Inspirery, the executive leader did not intend to join the industry until one of his relatives was diagnosed with cancer. The young adult watched as the relative fought helplessly with the disease. This situation changed his approach to life. He developed a strong will to work hard to revolutionize cancer treatment. He furthered his education and obtained a PhD in genetics before joining the cancer research industry for hands on experience. Clay co-founded Seattle Genetics in 1998. The biotech company specializes in making cancer therapies using the ADC technology.
When it was founded, Seattle Genetics operated on a tight budget. The company relied on investors to fund its research. This situation limited how far the company could venture out on its research. Clay decided to improve the company’s capital structure by floating the first Initial Public Offering (IPO) in 2000. The offering provided the company with millions of dollars that it used to fund its operations. Seattle Genetics advanced its therapies and released the first FDA-approved antibody drug conjugate therapy in 2011. The drug is doing well in the market. Clay helps the company to generate revenues by licensing its technology to other biotechnology firms. This strategy helps the company make extra money while also increasing the pace through which new and better cancer therapies are released. In the interview, Clay revealed that his company became profitable in 2010. The visionary leader encourages entrepreneurs to be patient.
About Clay Siegall
Dr. Clay Siegall is a shrewd entrepreneur and a genetics expert. The holder of a George Washington University’s doctorate in genetics is the chief executive officer of Seattle Genetics, a leading biotech firm, which is based in Seattle. Through his company, Dr. Clay develops viable cancer therapies using antibody drug conjugate technology.
Before founding Seattle Genetics, Clay worked for various cancer research institutions, including the National Cancer Institute, Bristol-Myers Squibb Pharmaceutical Research Institute and National Institutes of Health. The genetics expert has over 15 patents.